Stock ATE ANTIBE THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Antibe Therapeutics Inc.

Equities

ATE

CA0370255097

Market Closed - Toronto S.E.
Other stock markets
 11:00:00 2024-04-16 am EDT 		5-day change 1st Jan Change
0.295 CAD 0.00% Intraday chart for Antibe Therapeutics Inc. 0.00% -68.28%
Apr. 16 Antibe Therapeutics Says the TSX Reviewing a Potential Delisting of its Shares MT
Apr. 16 Antibe Therapeutics Brief: Announcing TSX Delisting Review MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Antibe Therapeutics Says the TSX Reviewing a Potential Delisting of its Shares
MT
Antibe Therapeutics Brief: Announcing TSX Delisting Review
MT
Antibe Announces TSX Delisting Review
BU
ANTIBE TO FILE AN APPLICATION FOR AN INITIAL ORDER UNDER COMPANIES CREDITORS ARRANGEMENT ACT
AQ
Antibe Announces Granting of Initial Order Under Companies' Creditors Arrangement Act
BU
DELETED: Canadian Investment Regulatory Organization Trade Resumption - ATE
AQ
Canadian Investment Regulatory Organization Trading Halt - ATE
AQ
Antibe to File an Application for an Initial Order Under Companies' Creditors Arrangement Act
BU
Antibe Therapeutics Brief: Says To File an Application for an Initial Order Under Companies' Creditors Arrangement Act
MT
Antibe Therapeutics Inc. Announces Board Resignations
CI
Toronto Stocks Edge Lower; Ballard Power Rises on Fuel-Cell Order
DJ
Antibe Therapeutics Shares Down on Clinical Hold on Otenaproxesul by U.S. Regulator
DJ
Antibe Therapeutics Brief: Down More Than 50% After Announcing FDA Clinical Hold on Otenaproxesul and Legal Action by Nuance
MT
Antibe Therapeutics Announces FDA Clinical Hold on Otenaproxesul and Legal Action by Nuance
MT
Antibe Therapeutics Brief: Announcing FDA Clinical Hold on Otenaproxesul and Legal Action by Nuance
MT
Antibe Announces FDA Clinical Hold on Otenaproxesul and Legal Action by Nuance
BU
Antibe Therapeutics Inc. Announces FDA Clinical Hold on Otenaproxesul
CI
Antibe Therapeutics Inc. Announces Formation of Executive Committee
CI
Antibe Therapeutics Brief: Says to Present Otenaproxesul PK/PD Results at the ASRA Pain Medicine Meeting
MT
Antibe to Present Otenaproxesul PK/PD Results at the ASRA Pain Medicine Meeting
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ATE Stock
  4. News Antibe Therapeutics Inc.